Bristol-Myers Squibb reports new drug data at EHA 2015

Bristol-Myers Squibb has presented new clinical research from its haematology portfolio at the European Hematology Association (EHA) annual congress in Austria.

Held in Vienna from June 11th to 14th, the conference saw the company present data on its investigational immunostimulatory antibody elotuzumab in the treatment of relapsed or refractory multiple myeloma.

Additionally, the company shared its latest insights on Opdivo in patients with relapsed or refractory lymphoid malignancies and Sprycel's performance in the treatment of chronic myeloid leukaemia.

The firm discussed real-world data for multiple compounds to advance the understanding of chronic myeloid leukaemia and multiple myeloma patient care.

Michael Giordano, senior vice-president and head of development for oncology at Bristol-Myers Squibb, said: "This data at EHA illustrates our commitment to transforming survival expectations for more patients with a variety of hematologic malignancies."

This comes after the firm presented its latest immuno-oncology research findings at the recent annual meeting of the American Society of Clinical Oncology.